Search Within

Eytan Moshe Stein

Formats
  1. Meeting Abstract (217)
  2. Journal Article (104)
  3. Review (17)
  4. Research Letter (14)
  5. Editorial (5)
  6. Book Section (3)
  7. Guidelines (2)
  8. Correspondence (1)
  9. Miscellaneous (1)
Groups
  1. Adult Leukemia (364)
  2. Center for Hematologic Malignancies (364)
  3. Department of Medicine (364)
  4. Hematologic Malignancies, Division of (364)
  5. GSK Faculty (92)
  6. Executive Committee, Center for Hematologic Malignancies (87)

More Groups

People
  1. Martin Tallman (116)
  2. Ross Levine (75)
  3. Aaron Goldberg (41)
  4. Jan Bewersdorf (33)
  5. Andriy Derkach (31)
  6. Christopher Famulare (30)

More People

Years
  1. 2025 (14)
  2. 2024 (44)
  3. 2023 (49)
  4. 2022 (34)
  5. 2021 (31)
  6. 2020 (30)

More Years

Publications
  1. Blood (170)
  2. Journal of Clinical Oncology (23)
  3. Clinical Lymphoma, Myeloma and Leukemia (17)
  4. Haematologica (16)
  5. Blood Advances (14)
  6. Leukemia and Lymphoma (12)

More Publications

Publishers
  1. American Society of Hematology (185)
  2. Elsevier Inc. (30)
  3. American Society of Clinical Oncology (27)
  4. Ferrata Storti Foundation (16)
  5. Nature Publishing Group (15)
  6. Taylor & Francis Group (12)

More Publishers

Results (364)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Healthcare resource utilization and costs in patients with myelodysplastic syndromes treated with hypomethylating agents: A SEER-Medicare analysis
    Journal Article

    Stein, E. M.; Bonifacio, G.; Latrémouille-Viau, D.; Shi, S.; Guérin, A.; Wu, E. Q.; Sadek, I.; Cao, X.
    Journal of Medical Economics (2021)

    Fulltext@MSK | Save
  • Mutant isocitrate dehydrogenase 1 inhibitor ivosidenib in combination with azacitidine for newly diagnosed acute myeloid leukemia
    Journal Article

    DiNardo, C. D.; Stein, A. S.; Stein, E. M.; Fathi, A. T.; Frankfurt, O.; Schuh, A. C.; Döhner, H.; Martinelli, G.; Patel, P. A.; Raffoux, E.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • A phase 1 study of LY3410738, a first-in-class covalent inhibitor of mutant IDH in advanced myeloid malignancies (trial in progress)
    Meeting Abstract

    Stein, E. M.; Konopleva, M.; Gilmour, R.; Szpurka, A. M.; Hill, E.; Ward, R.; Kantarjian, H. M.; Dinardo, C. D.
    Blood (2020)

    Fulltext@MSK | Save
  • Venetoclax therapy for relapsed and treatment refractory AML: Clinical outcomes and molecular predictors
    Meeting Abstract

    Stahl, M.; Menghrajani, K.; Derkach, A.; Chan, A.; Xiao, W.; Glass, J. L.; King, A. C.; Daniyan, A.; Famulare, C.; Cuello, B. M.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Clinical outcomes of acute myeloid leukemia patients bridged to allogeneic stem cell transplant by venetoclax combination therapy
    Meeting Abstract

    Stahl, M.; Menghrajani, K.; Derkach, A.; DeWolf, S.; Ruiz, J. D.; Ponce, D. M.; Shaffer, B. C.; Tamari, R.; Young, J. W.; Barker, J.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Initial results from a biomarker-directed phase 2 trial of SY-1425, a potent and selective RAR alpha agonist, in combination with azacitidine in relapsed/refractory acute myeloid leukemia
    Meeting Abstract

    Stein, E. M.; De Botton, S.; Cluzeau, T.; Pigneux, A.; Liesveld, J. L.; Cook, R. J.; Rousselot, P.; Rizzieri, D. A.; Braun, T.; Bixby, D. L.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Enasidenib (ENA) monotherapy with addition of azacitidine in non-responders is effective in older patients with newly diagnosed IDH2 mutated acute myeloid leukemia (AML): A completed phase 2/1b sub-study of the beat AML master trial
    Meeting Abstract

    Stein, E. M.; Huang, Y.; Borate, U.; Baer, M. R.; Stock, W.; Kovacsovics, T.; Blum, W.; Schiller, G. J.; Olin, R. L.; Foran, J. M.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Molecular predictors and effectiveness of measurable residual disease (MRD) eradication with chemotherapy and allogeneic stem cell transplantation for acute myeloid leukemia
    Meeting Abstract

    Stahl, M.; Derkach, A.; Famulare, C.; Cho, C.; Devlin, S.; Farnoud, N.; Menghrajani, K.; Patel, M. A.; Cai, S. F.; Geyer, M. B.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Impact of additional cytogenetic abnormalities and complex karyotype on event-free survival in acute promyelocytic leukemia: Analysis from a single academic center plus the APML4 study
    Meeting Abstract

    Epstein-Peterson, Z. D.; Rajeeve, S.; Derkach, A.; Park, J. H.; Stein, E. M.; Zhang, Y.; Iland, H. J.; Tallman, M. S.
    Blood (2020)

    Fulltext@MSK | Save
  • Molecular characterization of clinical response and relapse in patients with IDH1-mutant newly diagnosed acute myeloid leukemia treated with ivosidenib and azacitidine
    Meeting Abstract

    Daigle, S. R.; Choe, S.; DiNardo, C. D.; Stein, A. S.; Stein, E. M.; Fathi, A. T.; Frankfurt, O.; Schuh, A. C.; Döhner, H.; Martinelli, G.; more...
    Blood (2020)

    Fulltext@MSK | Save